Physician profile
Michael Pammit
NPI 1194012732
$1,967.95
in general payments reported to CMS, 2019-2025
29 companies · $253 in 2025
The $253 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $189 · 2020: $172 · 2021: $329 · 2022: $449 · 2023: $228 · 2024: $348 · 2025: $253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $829.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $829.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $356.86 | 2019-2023 | |
| Mayne Pharma Commercial LLC | $202.90 | 2021-2024 | |
| Exeltis, USA INC. | $183.33 | 2021-2025 | Slynd |
| Shield Therapeutics INC | $145.20 | 2023-2024 | Accrufer |
| Pfizer INC. | $110.51 | 2022-2023 | |
| Astellas Pharma US INC | $99.20 | 2024-2025 | Veozah |
| Sumitomo Pharma America, INC. | $87.84 | 2023-2025 | Myfembree |
| Avion Pharmaceuticals | $78.27 | 2020-2023 | Balcoltra |
| Allergan, INC. | $66.67 | 2019 | |
| Millicent US INC | $49.46 | 2024-2025 | Femring, Intrarosa, Femlyv |
| Novo Nordisk INC | $48.35 | 2023-2025 | Wegovy |
| Therapeuticsmd, INC. | $47.26 | 2021-2022 | |
| Evofem Biosciences, INC. | $45.86 | 2022-2023 | Phexxi |
| Agile Therapeutics, INC. | $44.24 | 2021-2022 | |
| Duchesnay USA Incorporated | $43.93 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $40.00 | 2020-2024 | Discovery Ci, 3dimensions |
| Bayer Healthcare Pharmaceuticals INC. | $37.67 | 2021-2025 | |
| Organon LLC | $36.47 | 2021-2022 | |
| Virtus Pharmaceuticals LLC | $35.63 | 2021-2022 | |
| Myovant Sciences INC. | $29.43 | 2022 | |
| Nevro Corp. | $26.64 | 2019 | |
| Daiichi Sankyo INC. | $24.33 | 2025 | Injectafer |
| Minerva Surgical, INC | $23.84 | 2022 | |
| Solventum Corporation | $19.99 | 2025 | Prevena |
| Exact Sciences Corporation | $19.84 | 2025 | Cologuard Collection Kit |
| Coloplast Corp | $17.96 | 2022 | |
| Scynexis, INC. | $15.85 | 2022 | |
| Roche Diagnostics Corporation | $15.46 | 2019 | |
| Amag Pharmaceuticals, INC. | $14.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Pammit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.